Informations générales (source: ClinicalTrials.gov)
Implementing Precision Medicine in cOmmunity HospiTALs (PRISM-POrTAL)
Interventional
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
juin 2022
avril 2025
15 août 2024
This is a prospective biomarker study that aims at demonstrating the impact of liquid
biopsy to deliver better treatment for cancer patients with metastatic disease managed in
the community setting
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Benjamin VERRET | 21/02/2024 16:47:06 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CENTRE HOSPITALIER SUD FRANCILIEN | Joel Ezenfis, MD | Contact (sur clinicalTrials) | |||
| GH PARIS SITE SAINT JOSEPH | Charles Naltet, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Eugène Marquis - 35042 - Rennes - France | Christophe Massard, MD | Contact (sur clinicalTrials) | |||
| Centre Hospitalier - 64046 - Pau - France | Kevin Bourcier, MD | Contact (sur clinicalTrials) | |||
| CH Annecy Genevois - 74370 - Épagny - France | Contact (sur clinicalTrials) | ||||
| CH de Bligny - Bligny - France | Ingrid Alexande, MD | Contact (sur clinicalTrials) | |||
| CH de la Côte Basque - 64100 - Bayonne - France | Thomas Grellety, MD | Contact (sur clinicalTrials) | |||
| CHU de La Réunion - 97448 - La Réunion - France | Mohamed KHETTAB, MD | Contact (sur clinicalTrials) | |||
| Clinique Saint-Jean l'ermitage - 77000 - Melun - France | Contact (sur clinicalTrials) | ||||
| GHM de Grenoble - 38028 - Grenoble - France | Contact (sur clinicalTrials) | ||||
| Groupement Hospitalier Diaconesses-Croix - 75020 - Paris - France | Antoine ANGELERGUES, MD | Contact (sur clinicalTrials) | |||
| HIA Bégin - 94160 - Saint-Mandé - France | Carole Hélissey, MD | Contact (sur clinicalTrials) | |||
| Hôpital Américain - 92200 - Neuilly-sur-Seine - France | Mahasti SAGHATCHIAN, Md | Contact (sur clinicalTrials) | |||
| Hôpital de la source - CHR d'Orléans - 45100 - Orléans - France | Heba DAWOOD, MD, PhD | Contact (sur clinicalTrials) | |||
| Hôpital Nord-Ouest Villefranche-sur-Saône - 69655 - Villefranche-sur-Saône - France | Boris Morel, MD | Contact (sur clinicalTrials) | |||
| Hôpitaux Privés de la Loire - 42100 - Saint-Étienne - France | Contact (sur clinicalTrials) | ||||
| Institut Mutualiste Montsouris - 75014 - Paris - France | David MALKA, MD, PhD | Contact (sur clinicalTrials) | |||
| Polyclinique Bordeaux Nord Aquitaine - 33300 - Bordeaux - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
Participants are eligible to be included in the study only if they meet all of the
following criteria:
1. Age ≥ 18 years
2. Histology: solid malignant tumor
3. Locally advanced/unresectable and/or metastatic (for prostate cancer: castration
resistant prostate cancer, for RH+/HER2- breast cancer: prior treatment with
endocrine therapy plus anti-CDK4/6 inhibitor)
4. Eastern Cooperative Oncology Group (ECOG) performance status < 2
5. Measurable disease as per RECIST criteria
6. Patient with a social security in compliance with the French law relating to
biomedical research (Article L.1121-11 of French Public Health Code)
7. Voluntary signed and dated written informed consent prior to any study specific
procedure.
Participants are eligible to be included in the study only if they meet all of the
following criteria:
1. Age ≥ 18 years
2. Histology: solid malignant tumor
3. Locally advanced/unresectable and/or metastatic (for prostate cancer: castration
resistant prostate cancer, for RH+/HER2- breast cancer: prior treatment with
endocrine therapy plus anti-CDK4/6 inhibitor)
4. Eastern Cooperative Oncology Group (ECOG) performance status < 2
5. Measurable disease as per RECIST criteria
6. Patient with a social security in compliance with the French law relating to
biomedical research (Article L.1121-11 of French Public Health Code)
7. Voluntary signed and dated written informed consent prior to any study specific
procedure.
Participants will be excluded from the study if they meet any of the following criteria:
1. Radiological evidence of symptomatic or progressive brain metastases
2. Previous or current malignancies of others histologies within the last 2 years, with
the exception of in situ carcinoma of the cervix, and adequately treated basal cell
or squamous cell carcinoma of the skin and prostate cancer
3. Any condition which in the Investigator's opinion makes it undesirable for the
subject to participate in a clinical trial or which would jeopardize compliance with
the protocol
4. Patient under guardianship or deprived of his liberty by a judicial or
administrative decision or incapable of giving its consent
5. Minors (Age < 18 years)
6. Pregnant or breast-feeding women
7. Previous enrollment in the present study.